As you've said, from 1 November 2018, changes to the misuse of drugs legislation has enabled unlicensed cannabis-based products to be prescribed by some doctors for medicinal use where there is a special clinical need. At the time, our chief pharmaceutical officer, Andrew Evans, said that the number of people in Wales who would be prescribed medicinal cannabis is likely to be very small. The interim guidance published is restrictive, and charities such as the MS Society say that nothing will change in the short term for the 10,000 people in the UK living with MS who could get relief from pain and muscle spasms by using medicinal cannabis.

Now, Sativex is only licensed for the treatment of spasticity, and then it's only available to a small group of people living with MS who meet the criteria. Now that the legislation's been changed, can the NHS in Wales make medicinal cannabis available to everyone who would benefit from it, or do we need to continue to hang on the coat-tails of the NHS in England? And will the Welsh Government review the interim guidance on prescribing medicinal cannabis so that access to the treatment is not so heavily restricted?